Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,052 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Adams S, et al. Among authors: liu mc. Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518. Ann Oncol. 2019. PMID: 30475947 Free article. Clinical Trial.
Response to W.C. Taylor, and C. Fiala and E.P. Diamandis.
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden M. Liu MC, et al. Ann Oncol. 2020 Sep;31(9):1268-1270. doi: 10.1016/j.annonc.2020.06.008. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32569726 Free article. No abstract available.
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ. Magbanua MJM, et al. Among authors: liu mc. Ann Oncol. 2021 Feb;32(2):229-239. doi: 10.1016/j.annonc.2020.11.007. Epub 2020 Nov 21. Ann Oncol. 2021. PMID: 33232761 Free PMC article.
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Du L, et al. Among authors: liu mc. Ann Oncol. 2021 May;32(5):642-651. doi: 10.1016/j.annonc.2021.02.011. Epub 2021 Feb 19. Ann Oncol. 2021. PMID: 33617937 Free article. Clinical Trial.
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, Chung G, Clement J, Gao J, Hunkapiller N, Jamshidi A, Kurtzman KN, Seiden MV, Swanton C, Liu MC. Klein EA, et al. Among authors: liu mc. Ann Oncol. 2021 Sep;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806. Epub 2021 Jun 24. Ann Oncol. 2021. PMID: 34176681 Free article.
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L; I-SPY Consortium. Marczyk M, et al. Among authors: liu mc. Ann Oncol. 2022 Aug;33(8):814-823. doi: 10.1016/j.annonc.2022.04.072. Epub 2022 May 2. Ann Oncol. 2022. PMID: 35513244 Free article. Clinical Trial.
Defining the subset of mutations in Polymerase Epsilon (POLE) associated with Loss-of-Proofreading (LOP) functionality.
Maddalena G, Zeineddine FA, Rivero-Hinojosa S, Aushev VN, Chowdhury S, Zeineddine MA, Yousef AM, Yap TA, EINaggar AC, Liu MC, White M, Overman MJ, Kopetz S, Shen JP. Maddalena G, et al. Among authors: liu mc. Ann Oncol. 2024 May 9:S0923-7534(24)00135-2. doi: 10.1016/j.annonc.2024.04.009. Online ahead of print. Ann Oncol. 2024. PMID: 38734075 No abstract available.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L. Bianchini G, et al. Among authors: liu mc. Ann Oncol. 2015 Dec;26(12):2429-36. doi: 10.1093/annonc/mdv395. Epub 2015 Sep 19. Ann Oncol. 2015. PMID: 26387142 Free article. Clinical Trial.
1,052 results